Axcella Announces Upcoming Presentation at J.P. Morgan Healthcare Conference
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company, announced its participation in the J.P. Morgan 2021 Healthcare Conference, scheduled for January 14, 2021, at 10:00 a.m. ET. The event will feature a live audio webcast available on the company’s website, with a replay accessible for 90 days post-presentation. Axcella focuses on treating complex diseases using endogenous metabolic modulator (EMM) compositions. Its pipeline includes candidates for non-alcoholic steatohepatitis (NASH) and reducing the risk of overt hepatic encephalopathy recurrence.
- None.
- None.
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the J.P. Morgan 2021 Healthcare Conference on January 14, 2021 at 10:00 a.m. ET.
A live audio webcast of this discussion will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com. A replay will also be available on Axcella’s website for 90 days following the presentation.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005072/en/
FAQ
When is Axcella presenting at the J.P. Morgan 2021 Healthcare Conference?
How can I listen to Axcella's presentation at the J.P. Morgan Conference?
What is Axcella's approach to treating complex diseases?
What are Axcella's lead therapeutic candidates focused on?
Will there be a replay of Axcella's conference presentation?
